Migsun (Naproxen Sodium, Sumatriptan Succinate)

naproxen sodium and sumatriptan succinate, the active ingredient in Migsun, is a NSAID and 5‑HT1B/1D receptor agonist combination presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults.

GNH USA supplies Migsun as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Migsun acts on migraine pathophysiology to provide rapid relief of headache and associated symptoms.

Migraine: reduces headache intensity and duration during an acute attack. Migraine with aura: alleviates visual and sensory disturbances accompanying the headache. Acute migraine attacks: offers prompt pain relief when taken at the onset of symptoms.

Migsun may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea - Dizziness - Dry mouth - Fatigue - Abdominal discomfort - Tingling sensations

Serious or Rare Side Effects: - Chest pain or tightness - Severe allergic reaction (anaphylaxis) - Serotonin syndrome - Cardiovascular events such as myocardial infarction - Marked hypertension - Hepatic dysfunction

Before prescribing Migsun, clinicians should evaluate patient-specific risk factors and monitor for adverse events.

Assess cardiovascular risk: avoid use in patients with uncontrolled heart disease. Evaluate for drug interactions: review concurrent serotonergic or NSAID therapies. Avoid use in uncontrolled hypertension: may exacerbate blood pressure. Use caution in hepatic or renal impairment: dose adjustment may be required. Monitor for signs of serotonin syndrome: especially when combined with other serotonergic agents. Store at ambient temperature: keep in original packaging, protect from moisture.

Migsun can interact with several medication classes; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - MAO inhibitors: risk of severe serotonin syndrome. - SSRIs, SNRIs, or other triptans: additive serotonergic effects. - Ergotamine derivatives: increased vasospasm risk. - Potent CYP2C9 inhibitors (e.g., fluconazole): may raise naproxen levels. - Anticoagulants (e.g., warfarin): heightened bleeding risk.

Moderate Interactions (Monitor Closely): - Antihypertensives: possible reduction in blood pressure control. - Diuretics: may affect renal clearance of naproxen. - Other NSAIDs: increased gastrointestinal toxicity. - CYP2C9 substrates (e.g., phenytoin): monitor plasma concentrations. - Alcohol: may enhance gastric irritation.